Establishing a UK National Preclinical Photon-FLASH Radiotherapy Facility (FLASH-SARRP)
Lead Research Organisation:
Queen's University of Belfast
Department Name: Sch of Medicine, Dentistry & Biomed Sci
Abstract
Radiotherapy treats cancers through the precise delivery of high doses of radiation to tumours, killing cancerous cells by damaging their DNA. While radiation can be precisely targeted to tumours, some normal tissue is also necessarily exposed to radiation, and avoiding excessive damage to normal tissue is a major limitation in the treatment of many cancers.
Currently, most radiotherapy is delivered using X-rays (photons) with individual treatments delivered over a period of minutes. However, recent evidence has suggested that delivering radiotherapy much more rapidly - with treatment times of less than a second - significantly reduces the damage radiation causes to normal tissue while retaining its efficacy against tumours. This has been dubbed the "FLASH effect", and has the potential to significantly improve the flexibility and efficacy of radiotherapy.
This effect has been unexpected, given established knowledge of how tumours respond to radiotherapy, and as a result is the subject of a significant amount of research. However, most of this research has been carried out using custom-designed radiation sources which expose cells to electrons, rather than photons as used in most clinical practice. Due to the novel nature of the FLASH effect, it is currently unknown if these different types of radiation interact with the FLASH effect in different ways, and how current information on the FLASH effect may be related to clinical practice.
This proposal seeks to provide funding for a first preclinical photon FLASH-SARRP (Small Animal Radiotherapy Research Platform). This would offer a unique resource, able to reproduce FLASH dose rates using photons in small animal models of cancer. This would enable the detailed exploration of the mechanisms of FLASH in the same modality as is used clinically, providing a unique insight into its underlying mechanisms and a valuable complement to existing resources within the UK.
We will use this source to validate the FLASH effect in photon exposures, and then explore its mechanistic basis, based on physical, chemical and biological effects within tumours and normal tissues. This work will be intergated into our established radiation biology research portfolio, and used to support the translation of FLASH into an effective clinical tool for the treatment of cancer.
Currently, most radiotherapy is delivered using X-rays (photons) with individual treatments delivered over a period of minutes. However, recent evidence has suggested that delivering radiotherapy much more rapidly - with treatment times of less than a second - significantly reduces the damage radiation causes to normal tissue while retaining its efficacy against tumours. This has been dubbed the "FLASH effect", and has the potential to significantly improve the flexibility and efficacy of radiotherapy.
This effect has been unexpected, given established knowledge of how tumours respond to radiotherapy, and as a result is the subject of a significant amount of research. However, most of this research has been carried out using custom-designed radiation sources which expose cells to electrons, rather than photons as used in most clinical practice. Due to the novel nature of the FLASH effect, it is currently unknown if these different types of radiation interact with the FLASH effect in different ways, and how current information on the FLASH effect may be related to clinical practice.
This proposal seeks to provide funding for a first preclinical photon FLASH-SARRP (Small Animal Radiotherapy Research Platform). This would offer a unique resource, able to reproduce FLASH dose rates using photons in small animal models of cancer. This would enable the detailed exploration of the mechanisms of FLASH in the same modality as is used clinically, providing a unique insight into its underlying mechanisms and a valuable complement to existing resources within the UK.
We will use this source to validate the FLASH effect in photon exposures, and then explore its mechanistic basis, based on physical, chemical and biological effects within tumours and normal tissues. This work will be intergated into our established radiation biology research portfolio, and used to support the translation of FLASH into an effective clinical tool for the treatment of cancer.
Technical Summary
Recent observations of the 'FLASH effect' suggest that exposing animals to radiation at high dose rates (>40 Gray/second) causes significantly less damage to normal tissues than a similar dose delivered at conventional (~Gray/minute) dose rates, while preserving tumour efficacy. This has the potential to significantly improve the therapeutic window in radiation therapy and improve outcomes. However, it remains poorly understood, with no consensus on the underlying mechanisms driving this effect.
A large amount of research is currently ongoing on the FLASH effect to attempt to quantify its effects and understand the underlying mechanisms. However, most of this research is currently carried out with either electrons or protons, despite the vast majority of clinical treatments being delivered with photons.
This proposal seeks to help bridge this gap by supporting the purchase of a FLASH-SARRP (Small Animal Radiotherapy Research Platform). This first-of-its-kind dedicated preclinical research platform offers FLASH dose rates (>100 Gray/second) coupled with advanced preclinical CT imaging enabling robust treatment planning and delivery. This would enable the validation and characterisation of the FLASH effect with a radiation modality much more closely matching clinical practice, potentially accelerating its translation as a clinical tool. This will also enable us to investigate the interaction of FLASH effects with other ongoing research, including prediction of intrinsic radiosensitivity, radiosensitiser development, and effects of spatial modulation of treatment.
This resource would integrate effectively with our existing infrastructure and expertise in small animal radiotherapy research and FLASH effects. It will also be made available as a research platform for other users, to foster a collaborative network across the UK and support links with other FLASH research modalities such as protons and electrons at other institutes.
A large amount of research is currently ongoing on the FLASH effect to attempt to quantify its effects and understand the underlying mechanisms. However, most of this research is currently carried out with either electrons or protons, despite the vast majority of clinical treatments being delivered with photons.
This proposal seeks to help bridge this gap by supporting the purchase of a FLASH-SARRP (Small Animal Radiotherapy Research Platform). This first-of-its-kind dedicated preclinical research platform offers FLASH dose rates (>100 Gray/second) coupled with advanced preclinical CT imaging enabling robust treatment planning and delivery. This would enable the validation and characterisation of the FLASH effect with a radiation modality much more closely matching clinical practice, potentially accelerating its translation as a clinical tool. This will also enable us to investigate the interaction of FLASH effects with other ongoing research, including prediction of intrinsic radiosensitivity, radiosensitiser development, and effects of spatial modulation of treatment.
This resource would integrate effectively with our existing infrastructure and expertise in small animal radiotherapy research and FLASH effects. It will also be made available as a research platform for other users, to foster a collaborative network across the UK and support links with other FLASH research modalities such as protons and electrons at other institutes.
Description | This award has supported the installation of the FLASH-SARRP technology at QUB. The FLASH-SARRP is a novel and innovative technology that is enabling new lines of research in the area of FLASH-radiothertapy. This approach could potentially reduced the adverse effects from radiation exposure during treatments. We now have the system in place and are initiating studies to understand how this approach can be used to benefit patients. |
Exploitation Route | This equipment award has supported a new program of research at QUB and significantly enhance the UK radiation research infrastructure. A number of research proposals have been submitted and will be initiated as part of this program. |
Sectors | Healthcare |
Description | Laboratory Tours for visting dignatories and lcoal charities |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Policymakers/politicians |
Results and Impact | Our lab has hosted several tours to showcase our work to visiting dignatories and lcoal charities which sparked questions and discussion afterwards, and the school reported increased interest in related subject areas. |
Year(s) Of Engagement Activity | 2023,2024 |
Description | Patrick G Johnston Centre for Cancer Research Open Day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Centre open day as part of NI Science week. More than 100 members of the public attended the Centre at which our research was discussed and shared with the attendees. |
Year(s) Of Engagement Activity | 2022,2023,2024 |
Description | Photon FLASH Research Consortium |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | An international research consortium led by Prof John Wong (Johns Hopkins University, USA) has been established to develop international collaborations across Cnetre using the FLASH-SARRP technology. Around 30 delegates attended the meeting in Toronto to discuss the challenges and research opportunities to be explored. I am a member of the research consortium and was invited to present at this meeting. |
Year(s) Of Engagement Activity | 2023 |